iTBra looks like a sports bra and consists of temperature sensors that collect up to 12 hours of normal and abnormal cellular activity associated with breast cancer. “It’s a wearable device with a number of sensors that check what happens with your circadian patterns of heat change on your breast over time,” said Cyrcadia CEO, Rob Royea.
The wearable is designed to take tissue density out of the detection equation, which is often a cause for inaccuracy in mammography screening. According to Cyrcadia, iTBra doesn’t rely on varying tissue densities in its screening. Instead, it measures temperature variances to identify abnormalities at early stages of abnormal cell growth and proliferation.
The results are then processed using sophisticated algorithms and transmitted to a smartphone via an app. “You wear the device for a few hours, and that information is automatically communicated to your physician,” said Royea.
Cyrcadia is collaborating with key organisation to develop iTBra; Cisco helped develop the algorithms for detecting and communicating the data; Flextronics is developing the wearable sensors; and Salesforce.com is responsible for the HIPPA-compliant interface and back-end database.
Royea hopes iTBra will be used by doctors in place of a mammogram, and then eventually consumers will be able to buy the product over the counter and use it for their monthly breast self-exam.
iTBra is expected to be available outside the US in the first quarter of 2016 and in the US in early to mid-2016 depending on FDA approval.